<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>315062</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>7636246</PubmedId>
            <Abstract>We identified functionally important regions of the DR(alpha, beta 1*0401) peptide binding site and present a model of bound peptide. DR(alpha, beta 1*0401)-restricted T cell recognition and peptide binding of Mycobacterium leprae (ML) peptide 38-50 and overlapping peptides from the 18-kDa heat-shock protein were analyzed. ML38-50 is unusual in its restricted binding pattern, binding to only one of five DR4 subtypes and no other DR molecules tested. Amino acid substitutions were introduced into ML38-50 and the DR(alpha, beta 1*0401) peptide binding site at positions likely to influence peptide-MHC or peptide- or MHC-TCR interactions. Peptide binding, T cell proliferation, and computer modeling studies suggest that residues 39F, 42E, and 44D of ML38-50 interact with pockets 1, 4, and 6, respectively, of the peptide binding site. Only DR(alpha, beta 1*0401) substitutions at residues in pockets 4 or 7 prevented binding of ML38-50, while multiple substitutions at other positions negatively affected its T cell recognition. In contrast, T cell recognition of some high affinity ML peptides that overlapped ML38-50, and contained N-terminal extensions, was only abolished with pocket 4 substitutions. An inverse correlation of peptide affinity for DR(alpha, beta 1*0401) with negative effects of MHC substitutions on T cell recognition of the overlapping ML peptides was observed. Thus, some regions, such as pocket 4, dominantly influence T cell recognition of multiple DR(alpha, beta 1*0401)-binding peptides. However, each DR(alpha, beta 1*0401)-binding peptide appears to have unique properties that determine the outcome of its MHC-peptide interactions and the relative importance of other polymorphic pockets.</Abstract>
            <ArticleYear>1995</ArticleYear>
            <ArticlePages>1951-63</ArticlePages>
            <ArticleTitle>Structural requirements of peptide and MHC for DR(alpha, beta 1*0401)-restricted T cell antigen recognition.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>McNicholl</LastName>
                    <ForeName>J M</ForeName>
                </Author>
                <Author>
                    <LastName>Whitworth</LastName>
                    <ForeName>W C</ForeName>
                </Author>
                <Author>
                    <LastName>Oftung</LastName>
                    <ForeName>F</ForeName>
                </Author>
                <Author>
                    <LastName>Fu</LastName>
                    <ForeName>X</ForeName>
                </Author>
                <Author>
                    <LastName>Shinnick</LastName>
                    <ForeName>T</ForeName>
                </Author>
                <Author>
                    <LastName>Jensen</LastName>
                    <ForeName>P E</ForeName>
                </Author>
                <Author>
                    <LastName>Simon</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Wohlhueter</LastName>
                    <ForeName>R M</ForeName>
                </Author>
                <Author>
                    <LastName>Karr</LastName>
                    <ForeName>R W</ForeName>
                </Author>
            </Authors>
            <Affiliations>Immunology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.</Affiliations>
            <ArticleChemicalList>HLA-DR Antigens;Peptide Fragments;Receptors, Antigen, T-Cell;Vaccines</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Autoimmune Diseases(immunology); Binding Sites; HLA-DR Antigens(chemistry; metabolism); Humans; Molecular Sequence Data; Mycobacterium leprae(immunology); Peptide Fragments(metabolism); Protein Structure, Secondary; Receptors, Antigen, T-Cell(metabolism); Structure-Activity Relationship; T-Lymphocytes(immunology); Vaccines(immunology)</ArticleMeshHeadingsList>
            <Comments>Data originally imported from the Database of Functional Molecular Immunology, FIMM (http://sdmc.lit.org.sg:8080/fimm/)</Comments>
            <Journal>
                <Volume>155</Volume>
                <Issue>4</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>ML38-50</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EFVVEFDLPGIKA</LinearSequence>
                        <StartingPosition>38</StartingPosition>
                        <EndingPosition>50</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>12105</EpitopeId>
                <ReferenceStartingPosition>38</ReferenceStartingPosition>
                <ReferenceEndingPosition>50</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Data originally imported from the Database of Functional Molecular Immunology, FIMM (http://sdmc.lit.org.sg:8080/fimm/) and recurated. The following refers to the epitope id as found in the original FIMM database: P000745.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2, 3, 4 and 5</LocationOfData>
                        <TCellId>315298</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>63</MhcAlleleId>
                                    <MhcAlleleId>407</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>1769</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Killed Mycobacterium leprae</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell CD4+</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>1769</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>A healthy donor was vaccinated with killed M. leprae. T cell clones 2/4F and 6/10F were cloned by limiting dilution and propagated by in vitro stimulation with whole M. leprae in the presence of irradiated autologous PBMC and IL-2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>63</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>ML38-50</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EFVVEFDLPGIKA</LinearSequence>
                                        <StartingPosition>38</StartingPosition>
                                        <EndingPosition>50</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P12809.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1769</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific T cell clones 2/4F and 6/10F proliferated in response to the epitope. Amino acid substitutions in the DRβ and DRα chains forming the predicted peptide and TCR binding sites were analyzed for their affect on the T cell proliferative response and relative binding to DRB1*0401. Analogues of the epitope with alanine or charged substitutions revealed that only residues 40Val and 47Gly were not esssential for recognition. The minimal epitopes for clones 6/10F and 2/4F were residues 38-48 and 39-47, respectively.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcBindingId>1353132</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML36-48</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GEEFVVEFDLPGI</LinearSequence>
                        <StartingPosition>36</StartingPosition>
                        <EndingPosition>48</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5</LocationOfData>
                <EpitopeId>19240</EpitopeId>
                <ReferenceStartingPosition>36</ReferenceStartingPosition>
                <ReferenceEndingPosition>48</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcBindingId>1353133</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML37-49</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EEFVVEFDLPGIK</LinearSequence>
                        <StartingPosition>37</StartingPosition>
                        <EndingPosition>49</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5</LocationOfData>
                <EpitopeId>11638</EpitopeId>
                <ReferenceStartingPosition>37</ReferenceStartingPosition>
                <ReferenceEndingPosition>49</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcBindingId>1353136</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML39-51</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FVVEFDLPGIKAD</LinearSequence>
                        <StartingPosition>39</StartingPosition>
                        <EndingPosition>51</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5</LocationOfData>
                <EpitopeId>18313</EpitopeId>
                <ReferenceStartingPosition>39</ReferenceStartingPosition>
                <ReferenceEndingPosition>51</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcBindingId>1353137</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML35-47</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EGEEFVVEFDLPG</LinearSequence>
                        <StartingPosition>35</StartingPosition>
                        <EndingPosition>47</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5</LocationOfData>
                <EpitopeId>12153</EpitopeId>
                <ReferenceStartingPosition>35</ReferenceStartingPosition>
                <ReferenceEndingPosition>47</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6 and Text P. 1956</LocationOfData>
                        <MhcBindingId>1353139</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope competed weakly at 100 µM with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML34-46</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>REGEEFVVEFDLP</LinearSequence>
                        <StartingPosition>34</StartingPosition>
                        <EndingPosition>46</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5 and Swiss-Prot record</LocationOfData>
                <EpitopeId>53504</EpitopeId>
                <ReferenceStartingPosition>34</ReferenceStartingPosition>
                <ReferenceEndingPosition>46</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcBindingId>1353141</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The epitope did not compete with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML32-44</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AWREGEEFVVEFD</LinearSequence>
                        <StartingPosition>32</StartingPosition>
                        <EndingPosition>44</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5 and Swiss-Prot record</LocationOfData>
                <EpitopeId>5689</EpitopeId>
                <ReferenceStartingPosition>32</ReferenceStartingPosition>
                <ReferenceEndingPosition>44</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcBindingId>1353143</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The epitope did not compete with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML31-43</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DAWREGEEFVVEF</LinearSequence>
                        <StartingPosition>31</StartingPosition>
                        <EndingPosition>43</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5 and Swiss-Prot record</LocationOfData>
                <EpitopeId>7679</EpitopeId>
                <ReferenceStartingPosition>31</ReferenceStartingPosition>
                <ReferenceEndingPosition>43</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcBindingId>1353146</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The epitope did not compete with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(38A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>AFVVEFDLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>1418</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353200</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 38Glu in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(38K)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>KFVVEFDLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>30881</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353209</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has a Lys substitution of 38Glu in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(39A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EAVVEFDLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>11217</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353210</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>An Ala substitution of 39Phe in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA) abolished binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(40A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFAVEFDLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>11949</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353211</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 40Val in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(41A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVAEFDLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12091</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353212</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 41Val in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(42A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVAFDLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12096</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353215</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 42Glu in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(42K)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVKFDLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12107</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353216</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>A Lys substitution of 42Glu in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA) abolished binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(43A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEADLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12097</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353217</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 43Phe in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(44A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEFALPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12098</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353218</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 44Asp in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(44K)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEFKLPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12106</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353219</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>A Lys substitution of 44Asp in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA) abolished binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(45A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEFDAPGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12099</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353221</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 45Leu in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(46A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEFDLAGIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12100</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353222</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 46Pro in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(47A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEFDLPAIKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12101</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353223</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 47Gly in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(48A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEFDLPGAKA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12102</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353224</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 48Ile in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(49A)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEFDLPGIAA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12103</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353225</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has an Ala substitution of 49Lys in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML38-50(49E)</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>EFVVEFDLPGIEA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>12104</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 4</LocationOfData>
                        <MhcBindingId>1353226</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope, which has a Glu substitution of 49Lys in the M. leprae peptide ML 38-50 (EFVVEFDLPGIKA), competed with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ML40-52</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VVEFDLPGIKADS</LinearSequence>
                        <StartingPosition>40</StartingPosition>
                        <EndingPosition>52</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12809.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1769</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 5 and Swiss-Prot record</LocationOfData>
                <EpitopeId>71648</EpitopeId>
                <ReferenceStartingPosition>40</ReferenceStartingPosition>
                <ReferenceEndingPosition>52</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcBindingId>1353233</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>24</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The epitope did not compete with biotinylated HA306-318 for binding to HLA-DRB1*0401 expressed on L cells.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

